Imricor Medical Systems, Inc. (ASX:IMR)
Australia · Delayed Price · Currency is AUD | Market Cap | 651.99M +17.0% |
| Revenue (ttm) | 438.23K -69.5% |
| Net Income | -37.96M |
| EPS | -0.12 |
| Shares Out | 353.38M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 249,837 |
| Average Volume | 297,651 |
| Open | 1.840 |
| Previous Close | 1.845 |
| Day's Range | 1.710 - 1.840 |
| 52-Week Range | 1.150 - 2.250 |
| Beta | 0.41 |
| RSI | 45.96 |
| Earnings Date | May 13, 2026 |
About Imricor Medical Systems
Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the United States, Europe, and the Middle East. The company’s products include Vision-MR Ablation Catheter 2.0, a MR-compatible cardiac ablation catheter; Vision-MR Diagnostic Catheter, a MR-compatible diagnostic catheter; NorthStar mapping system, a real-time, high-resolution soft tissue imaging of MRI to guide and visualize procedures with except... [Read more]
Financial Performance
In 2025, Imricor Medical Systems's revenue was $292,309, a decrease of -69.53% compared to the previous year's $959,424. Losses were -$25.32 million, -14.73% less than in 2024.
Financial numbers in USD Financial StatementsNews
Imricor Medical Systems Transcript: AGM 2026
Significant clinical and regulatory milestones were achieved in 2025, including the first MR ventricular tachycardia ablation and expansion in Europe. All resolutions, including director elections and equity plan amendments, were put to vote, with results to be released to the ASX.
Imricor Medical Systems Earnings Call Transcript: H2 2025
Major regulatory and clinical milestones achieved, including first-in-human MRI-guided VT ablation and FDA clearance for NorthStar. Revenue declined due to trial-related non-revenue procedures, but commercial readiness and pipeline growth position the company for significant expansion as approvals progress.
Imricor Medical Systems Earnings Call Transcript: H1 2025
Revenue declined 52% year-over-year due to lower equipment sales, while net loss rose to $13.1 million, driven by fair value changes and increased investment in sales and R&D. Regulatory progress continues, with Northstar FDA approval and U.S. launch expected by year-end, and a strong cash position supports ongoing expansion.
Imricor Medical Systems Transcript: AGM 2025
The meeting covered global commercialization progress, new clinical applications, and recent financing that supports strategic growth. Key resolutions included director elections, equity plan approvals, and auditor ratification, with voting results to be released to the ASX.
Imricor Medical Systems Transcript: NWR Virtual Healthcare Conference
MRI-guided cardiac ablation offers superior efficacy and cost savings over traditional X-ray methods, with strong clinical results and a $10 billion global market opportunity. Regulatory progress and a recent $70 million capital raise position the company for rapid global expansion and commercialization.
Imricor Medical Systems Earnings Call Transcript: H2 2024
Achieved 56% revenue growth in 2024, driven by new device approvals and expanding global commercialization. Anticipates major regulatory milestones and broader adoption in 2025, with Northstar and PFA programs as key growth drivers.
Imricor Medical Systems Transcript: EGM 2024
Shareholders voted on ratifying prior share issues and approving new placements in two tranches, with no questions raised. Voting results, representing 37.15% of issued capital, will be released to the ASX later today.
Imricor Medical Systems Earnings Call Transcript: H1 2024
Revenue doubled year-over-year to $408,000, with net loss improving 26%. Regulatory and commercial milestones were achieved globally, and new capital raised is expected to fund operations into 2026. U.S. FDA trial and first MRI-guided VT ablation are key near-term catalysts.